Please login to the form below

Not currently logged in
Email:
Password:

Par to acquire Indian generics firm

US-based Par Pharmaceutical has entered into a definitive agreement to acquire India's Edict Pharmaceuticals, a privately held developer and manufacturer of solid oral dosage generic pharmaceuticals

The US-based speciality pharma company Par Pharmaceutical has entered into a definitive agreement to acquire India's Edict Pharmaceuticals, a privately held developer and manufacturer of solid oral dosage generic pharmaceuticals.

Par will pay up to $37.6m in cash for the company, as well as making repayment of certain additional pre-close indebtedness.  The transaction is expected to be completed by the end of this year and to be accretive to Par's earnings in 2013.

Par was attracted to Edict largely because of the Indian company's "highly-skilled research and development team and strong product pipeline focused on niche first-to-file, first-to-market formulations," the US firm said.

Edict currently has seven abbreviated new drug applications (ANDAs) for generic products under its own name pending with the US Food and Drug Administration, as well as one ANDA filed in the US in the name of a development partner, and another 14 generic products in various stages of development.

Edict is focused entirely on developing and manufacturing products for export to the US and other regulated markets, offering "US standards at Indian costs," according to the company's promotional materials.

Par and Edict have already collaborated on a number of Par's generic products and have a longstanding working relationship, the companies noted.

24th May 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Bedrock Healthcare Communications

Bedrock Healthcare Communications is an award-winning, independent agency founded in 2011. We partner with healthcare professionals, patients, and global pharmaceutical...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...